308 related articles for article (PubMed ID: 27037420)
1. Genetic Modifiers of the p53 Pathway.
Basu S; Murphy ME
Cold Spring Harb Perspect Med; 2016 Apr; 6(4):a026302. PubMed ID: 27037420
[TBL] [Abstract][Full Text] [Related]
2. Altered tumor formation and evolutionary selection of genetic variants in the human MDM4 oncogene.
Atwal GS; Kirchhoff T; Bond EE; Montagna M; Menin C; Bertorelle R; Scaini MC; Bartel F; Böhnke A; Pempe C; Gradhand E; Hauptmann S; Offit K; Levine AJ; Bond GL
Proc Natl Acad Sci U S A; 2009 Jun; 106(25):10236-41. PubMed ID: 19497887
[TBL] [Abstract][Full Text] [Related]
3. Effects of MDM2, MDM4 and TP53 codon 72 polymorphisms on cancer risk in a cohort study of carriers of TP53 germline mutations.
Fang S; Krahe R; Lozano G; Han Y; Chen W; Post SM; Zhang B; Wilson CD; Bachinski LL; Strong LC; Amos CI
PLoS One; 2010 May; 5(5):e10813. PubMed ID: 20520810
[TBL] [Abstract][Full Text] [Related]
4. Functional MDM4 rs4245739 genetic variant, alone and in combination with P53 Arg72Pro polymorphism, contributes to breast cancer susceptibility.
Liu J; Tang X; Li M; Lu C; Shi J; Zhou L; Yuan Q; Yang M
Breast Cancer Res Treat; 2013 Jul; 140(1):151-7. PubMed ID: 23793604
[TBL] [Abstract][Full Text] [Related]
5. Dysfunction of p53 pathway in human colorectal cancer: analysis of p53 gene mutation and the expression of the p53-associated factors p14ARF, p33ING1, p21WAF1 and MDM2.
Tachibana M; Kawamata H; Fujimori T; Omotehara F; Horiuchi H; Ohkura Y; Igarashi S; Kotake K; Kubota K
Int J Oncol; 2004 Oct; 25(4):913-20. PubMed ID: 15375540
[TBL] [Abstract][Full Text] [Related]
6. Prevalence, causes and impact of TP53-loss phenocopying events in human tumors.
Fito-Lopez B; Salvadores M; Alvarez MM; Supek F
BMC Biol; 2023 Apr; 21(1):92. PubMed ID: 37095494
[TBL] [Abstract][Full Text] [Related]
7. Genetic association of single nucleotide polymorphisms in P53 pathway with gastric cancer risk in a Chinese Han population.
Wu GC; Zhang ZT
Med Oncol; 2015 Jan; 32(1):401. PubMed ID: 25479941
[TBL] [Abstract][Full Text] [Related]
8. Deregulation of the TP53/p14ARF tumor suppressor pathway in low-grade diffuse astrocytomas and its influence on clinical course.
Watanabe T; Katayama Y; Yoshino A; Komine C; Yokoyama T
Clin Cancer Res; 2003 Oct; 9(13):4884-90. PubMed ID: 14581362
[TBL] [Abstract][Full Text] [Related]
9. Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities.
Ichimura K; Bolin MB; Goike HM; Schmidt EE; Moshref A; Collins VP
Cancer Res; 2000 Jan; 60(2):417-24. PubMed ID: 10667596
[TBL] [Abstract][Full Text] [Related]
10. Single-nucleotide polymorphisms in p53 pathway and aggressiveness of prostate cancer in a Caucasian population.
Sun T; Lee GS; Oh WK; Pomerantz M; Yang M; Xie W; Freedman ML; Kantoff PW
Clin Cancer Res; 2010 Nov; 16(21):5244-51. PubMed ID: 20855462
[TBL] [Abstract][Full Text] [Related]
11. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans.
Bond GL; Hu W; Bond EE; Robins H; Lutzker SG; Arva NC; Bargonetti J; Bartel F; Taubert H; Wuerl P; Onel K; Yip L; Hwang SJ; Strong LC; Lozano G; Levine AJ
Cell; 2004 Nov; 119(5):591-602. PubMed ID: 15550242
[TBL] [Abstract][Full Text] [Related]
12. Switching mechanisms of cell death in mdm2- and mdm4-null mice by deletion of p53 downstream targets.
Chavez-Reyes A; Parant JM; Amelse LL; de Oca Luna RM; Korsmeyer SJ; Lozano G
Cancer Res; 2003 Dec; 63(24):8664-9. PubMed ID: 14695178
[TBL] [Abstract][Full Text] [Related]
13. Augmented antitumor activity of 5-fluorouracil by double knockdown of MDM4 and MDM2 in colon and gastric cancer cells.
Imanishi M; Yamamoto Y; Wang X; Sugaya A; Hirose M; Endo S; Natori Y; Yamato K; Hyodo I
Cancer Sci; 2019 Feb; 110(2):639-649. PubMed ID: 30488540
[TBL] [Abstract][Full Text] [Related]
14. p53 as a target for the treatment of cancer.
Duffy MJ; Synnott NC; McGowan PM; Crown J; O'Connor D; Gallagher WM
Cancer Treat Rev; 2014 Dec; 40(10):1153-60. PubMed ID: 25455730
[TBL] [Abstract][Full Text] [Related]
15. When the guardian sleeps: Reactivation of the p53 pathway in cancer.
Merkel O; Taylor N; Prutsch N; Staber PB; Moriggl R; Turner SD; Kenner L
Mutat Res Rev Mutat Res; 2017 Jul; 773():1-13. PubMed ID: 28927521
[TBL] [Abstract][Full Text] [Related]
16. The expression of MDM2, MDM4, p53 and p21 in myeloid neoplasms and the effect of MDM2/MDM4 dual inhibitor.
Eskandari M; Shi Y; Liu J; Albanese J; Goel S; Verma A; Wang Y
Leuk Lymphoma; 2021 Jan; 62(1):167-175. PubMed ID: 32924682
[TBL] [Abstract][Full Text] [Related]
17. Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry?
Wade M; Wahl GM
Mol Cancer Res; 2009 Jan; 7(1):1-11. PubMed ID: 19147532
[TBL] [Abstract][Full Text] [Related]
18. MDM2 is a central node in the p53 pathway: 12 years and counting.
Bond GL; Hu W; Levine AJ
Curr Cancer Drug Targets; 2005 Feb; 5(1):3-8. PubMed ID: 15720184
[TBL] [Abstract][Full Text] [Related]
19. Genetic variants in p53-related genes confer susceptibility to second primary malignancy in patients with index squamous cell carcinoma of head and neck.
Jin L; Sturgis EM; Zhang Y; Huang Z; Wei P; Guo W; Wang Z; Wei Q; Song X; Li G
Carcinogenesis; 2013 Jul; 34(7):1551-7. PubMed ID: 23508638
[TBL] [Abstract][Full Text] [Related]
20. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis.
Eischen CM; Weber JD; Roussel MF; Sherr CJ; Cleveland JL
Genes Dev; 1999 Oct; 13(20):2658-69. PubMed ID: 10541552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]